Amorcyte Secures Production Capacity for Lead Cell Therapy Product; Progenitor Cell Therapy LLC is Retained to Develop and Manufacture AMR-001.HACKENSACK, N.J. -- Amorcyte Inc (Amorcyte), a privately funded biotechnology company developing cell therapy products to treat cardiovascular disease, announced today that it has signed an exclusive agreement for the development and manufacturing of Amorcyte's lead product, AMR-001, with Progenitor Cell Therapy, LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control (PCT (Private Communications Technology) A protocol from Microsoft that provides secure transactions over the Web. See security protocol. ), a leading full service cell therapy development and contract manufacturing company. "The product development and manufacturing agreement with Progenitor Cell Therapy is a critical component of our corporate and product development plan," explains Dr. Thomas Moss, Amorcyte's Chief Medical Officer. "Our strategic relationship with PCT enables our development team to draw on PCT's unique and extensive investigative, regulatory and commercial experience in the applied cell therapy field." "Leveraging PCT for development of AMR-001 will allow Amorcyte to reduce capital outlay. This will contribute to efficient conduct of the clinical trial for AMR-001, while enabling Amorcyte to pursue other potential related product development opportunities," said President of Progenitor Cell Therapy, Dr. Robert Preti. AMR-001 is an autologous autologous /au·tol·o·gous/ (aw-tol´ah-gus) related to self; belonging to the same organism. au·tol·o·gous adj. 1. bone marrow-derived cell product being tested to determine if its infusion into the coronary (heart) artery after myocardial infarct can restore heart muscle function in tissue damaged by the heart attack. Forty men and women who have had a recent heart attack and meet criteria will be asked to take part in this study. The Phase I trial is now open at Emory University School of Medicine under Principal Investigator, Arshed A. Quyyumi, M.D., FRCP FRCP Fellow of the Royal College of Physicians. FRCP abbr. Fellow of the Royal College of Physicians , FACC FACC Fellow, American College of Cardiology . Amorcyte is in final negotiations to open the trial in another leading cardiology center within 90 days. Amorcyte is actively recruiting patients for the trial. About Cardiovascular Disease It is estimated there are approximately 1.1 million instances of acute myocardial infarction acute myocardial infarction (  ·kyōōtˑ mī·ō·karˑ·dē· , 12 million cases of chronic ischemia, and 5 million occurrences of congestive heart failure congestive heart failure, inability of the heart to expel sufficient blood to keep pace with the metabolic demands of the body. In the healthy individual the heart can tolerate large increases of workload for a considerable length of time. in the United States per year. A significant percentage of these patients are in need of additional therapies to ameliorate the symptoms of their disease. Products like AMR-001 are now under active investigation to determine safety and potential biologic activity. About Amorcyte Inc Amorcyte Inc is a therapeutics company pursuing cell based therapies for cardiovascular diseases, reimbursable on a commercial scale for widespread clinical use. Amorcyte was incorporated in May 2005 and received FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval for its Phase I trial IND in September 2005. Watch for the launch of www.amorcyte.com coming soon. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion